Figure 4.

Specific CD8⁺ T cells accumulate in the spleen and lymph node and do not migrate into the heart after anti-LFA-1 treatment. A/Sn mice were immunized with ASP-2 using the heterologous “prime-boost” vaccination regimen, infected with 150 trypomastigotes forms of Trypanosoma cruzi and treated with anti-LFA-1 or isotype control until the 20th after infection. In this day, spleen, heart, liver, lymph nodes, and blood cells of the immunized, infected, and treated or not with anti-LFA-1 were labeled with anti-CD8 and H2K^K-TEWETGQI multimer. (A) Frequency of specific CD8⁺ T cells in the spleen, lymph node, blood, heart, and liver, respectively. (B–F) Absolute number of specific CD8⁺ T cells in the spleen, lymph node, blood, heart, and liver, respectively. The results for the spleen, lymph node, and liver are representative values of an individual in each group (n = 4) with mean ± SD. While the results for the blood and heart were taken from a pool of five individuals per group, values of an individual of each repetition (n = 2) with mean ± SD. Statistical analysis was performed using the one-way ANOVA. (G) Histograms represent MFI of specific CD8⁺ T cells that express CD11a onto the surface in the spleen, blood, and heart, respectively, and the group naïve the MFI of CD11a was analyzed onto the surface of CD8⁺ T cells. Asterisks denote statistically significant differences between of groups 2 and 3 (**P < 0.001).